表纸
市场调查报告书

糖尿病的诊断、治疗的全球市场

Global Markets for Diabetes Therapeutics and Diagnostics

出版商 BCC Research 商品编码 124293
出版日期 内容资讯 英文 155 Pages
订单完成后即时交付
价格
Back to Top
糖尿病的诊断、治疗的全球市场 Global Markets for Diabetes Therapeutics and Diagnostics
出版日期: 2016年09月20日内容资讯: 英文 155 Pages
简介

全球糖尿病诊断、治疗市场规模预计从2016年到2021年以4.4%的年复合成长率发展,从2016年的1250亿美元,成长到2021年的1550亿美元的规模。

本报告提供糖尿病的诊断及治疗的药物及设备的市场调查,糖尿病概要,目前治疗方法,主要药物、设备、其他相关产品与供应商概要,产品及药物的开发趋势,各产品类型、地区的市场规模的变化与预测,主要国家市场详细分析,以及主要企业的简介等汇整。

第1章 简介

第2章 摘要

  • 糖尿病市场
  • 主要企业

第3章 概要

  • 糖尿病的基础资讯
    • 糖尿病市场结构
    • 成长推动因素
    • 市场成长率
  • 目前糖尿病治疗
    • 胰岛素
    • 口服抗糖尿病药物
    • 监测设备
    • 地区区分
    • 市场成长
    • 糖尿病产业
      • 医药品企业
      • 医疗设备企业

第4章 产品、供应商

  • 胰岛素
    • 概要
    • 胰岛素供给企业
  • 胰岛素给药
    • 注射器
      • 制造商
      • 制造商
    • 注射器
    • 胰岛素帮浦
      • 供给业者
  • 口服降血糖药
    • 磺醯尿素类剂
    • Biguanides
    • Alpha-Glucosidase Inhibitors
    • Glitazone
    • 饭后血糖调节药 (PGR:prandial glucose regulator)
    • GLP-1类比 (肠降糖素类似物)
    • Amylin模仿药
  • 诊断、监测
    • 自我监测所扮演的角色
  • 血糖值监测设备与供应商
    • 采血针
    • 采血设备
    • 血糖值监测器
    • 血糖值测量仪的准确度
  • 其他检验方法
    • 血红素A1C
  • 糖尿病监测的支援软体

第5章 新的开发

  • 新的筹备、组合
    • 新的胰岛素递送技术
  • 改良型的口服抗糖尿病药物
  • 血糖值检验的新的开发
    • 持续血糖检测 (CGM)
    • 非侵袭监测
  • 急进的方法
    • 胰岛素的替代
    • 免疫疗法
    • 移植
    • 细胞、干细胞治疗
    • 基因治疗

第6章 全球糖尿病市场

  • 市场结构
    • 市场规模
  • 市场分析:各产品类型
    • 胰岛素&胰岛素递送设备
    • 其他糖尿病治疗药
    • 胰岛素帮浦
    • 监测产品
  • 趋势
  • 地区市场
  • 国家市场
  • 国家市场:详细内容

第7章 企业简介

  • 主要企业
    • A. MENARINI DIAGNOSTICS S.R.L.
    • ABBOTT LABORATORIES
    • ASCENSIA
    • BECTON DICKINSON
    • ELI LILLY AND CO.
    • GLAXO SMITHKLINE
    • JOHNSON & JOHNSON
    • MEDTRONIC
    • MERCK KGAA
    • MERCK & CO.
    • NOVARTIS PHARMA AG
    • NOVO NORDISK A/S
    • ROCHE
    • SANOFI
    • 武田药品工业
  • 其他的企业
    • 77 ELEKTRONIKA KFT.
    • AGAMATRIX INC.
    • ANIMAS CORP.
    • DEBIOTECH S.A.
    • INLIGHT SOLUTIONS INC.
    • LIFESCAN INC.
    • Nipro
    • OWEN MUMFORD LTD.
    • PALCO LABS INC.
    • Terumo Corporation

第8章 附录I:关于糖尿病

第9章 附录II:用语

图表

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: HLC029E

The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.

This report provides:

  • An overview of the global market for diabetes
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
  • Analysis of the devices and instruments used in the diagnosis and monitoring of diabetes
  • A close look at major forces contributing to the vigorous growth of the diabetes market
  • Evaluation of other factors influencing the market such as health care policies, demographics, and the wider economic environment
  • Discussion covering companies in the relevant pharmaceutical and medical industries through company profiles of many leading players in the field

image1

REPORT SCOPE

This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.

A comprehensive refresher section on diabetes is provided as an appendix.

ANALYST'S CREDENTIALS

Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous BCC Research reports on the diabetes marketplace covering both therapeutic and monitoring aspects.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • MARKET ANALYSES AND FORECASTS
  • METHODOLOGY
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • THE DIABETES MARKET
  • LEADING COMPANIES
  • SUMMARY TABLE GLOBAL DIABETES MARKET BY PRODUCT GROUP, THROUGH 2021 ($ BILLIONS)
  • SUMMARY FIGURE GLOBAL DIABETES MARKET BY PRODUCT GROUP, 2015-2021 ($ BILLIONS)

CHAPTER 3 OVERVIEW

  • DIABETES BASICS
    • STRUCTURE OF THE DIABETES MARKET
    • DRIVERS FOR GROWTH
      • Rising Prevalence
      • TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE CASES, 2015-2040 (MILLIONS)
      • New Technology
    • RATE OF MARKET GROWTH
  • CURRENT TREATMENT OF DIABETES
    • INSULIN
      • Insulin Administration Devices
    • ORAL ANTIDIABETIC DRUGS
    • MONITORING DEVICES FOR DIABETES
    • TABLE 2 GLOBAL DIABETES MARKET, 2015 ($ BILLIONS)
    • REGIONAL SEGMENTATION
    • TABLE 3 ADULT DIABETES MARKET BY REGION, 2015 ($ MILLIONS/%)
    • MARKET GROWTH
    • THE DIABETES INDUSTRY
    • PHARMACEUTICAL COMPANIES
    • MEDICAL DEVICE COMPANIES

CHAPTER 4 PRODUCTS AND SUPPLIERS

  • INSULIN
    • HISTORY
      • Bovine and Porcine Insulins
      • Humanized Insulin
    • COMPANIES SUPPLYING INSULIN
      • Eli Lilly
      • Sanofi
      • Novo Nordisk
      • Other Suppliers
        • Wockhardt Ltd. (India)
        • Biocon Ltd. (India)
        • Diosynth (the Netherlands)
        • TABLE 4 MAJOR BRANDS OF INSULIN
  • INSULIN DELIVERY
    • SYRINGES
    • INSULIN SYRINGE MANUFACTURERS
      • Becton Dickinson
      • Owen Mumford
      • Terumo
      • B. Braun
    • PENS
    • TABLE 5 INSULIN PENS
    • MANUFACTURERS OF INSULIN PENS
      • Novo Nordisk
      • Owen Mumford
      • Other Makers
    • INJECTORS
    • TABLE 6 INSULIN INJECTORS
    • INSULIN PUMPS
      • Defining an Insulin Pump
      • Infusion Sets
      • Candidates for Pump Therapy
    • COMPANIES SUPPLYING INSULIN PUMPS
      • Animas Corp.
      • Sooil Development Co.
      • Medtronic MiniMed
      • Roche Disetronic
      • Problems with Pumps or Users?
  • ORAL HYPOGLYCEMIC DRUGS
    • SULFONYLUREAS
    • TABLE 7 SULFONYLUREAS
    • BIGUANIDES
    • ALPHA-GLUCOSIDASE INHIBITOR
    • GLITAZONES
    • PRANDIAL GLUCOSE REGULATORS
    • GLP-1 ANALOGS; ALSO KNOWN AS INCRETIN MIMETICS
    • AMYLIN MIMETIC
    • TABLE 8 ORAL HYPOGLYCEMICS
  • DIAGNOSIS AND MONITORING
    • THE ROLE OF SELF-MONITORING
      • SMBG Frequency
  • BLOOD GLUCOSE MONITORING DEVICES AND SUPPLIERS
    • LANCETS
    • TABLE 9 GLOBAL SUPPLIERS OF BLOOD LANCETS
    • BLOOD SAMPLING DEVICES
      • Ascensia
      • Becton Dickinson
      • Cell Robotics
      • LifeScan
      • Roche Diagnostics
    • BLOOD GLUCOSE MONITORS
    • TABLE 10 MAJOR BLOOD GLUCOSE MONITOR SUPPLIERS AND BRANDS
      • 77 Elektronica Kft
      • A. Menarini Diagnostics
      • Abbott Laboratories
      • Acon Laboratories Inc.
      • AgaMatrix Inc.
      • Apex Biotechnology Corp.
      • Arkray USA
      • Ascensia
      • Aventir Biotech LLC
      • Belbiosens
      • Diagnostic Devices Inc.
      • Eumed Biotechnology Co. Ltd.
      • HMD Bio Medical
      • GlucoPlus Inc.
      • Health & Life Co.
      • HemoCue AB
      • Home Diagnostics Inc.
      • Hypoguard
      • i-Sens Inc.
      • LifeScan Inc.
      • Medtronic MiniMed
      • National Diagnostic Products
      • Novabiomedical Corp.
      • Roche
      • TaiDoc Technology Corp.
      • US Diagnostics Inc.
    • GLUCOSE METER ACCURACY
  • OTHER TESTING APPROACHES
    • HEMOGLOBIN A1C
      • Hemoglobin A1c Meters
  • SOFTWARE AIDS TO DIABETES MONITORING

CHAPTER 5 NEW DEVELOPMENTS IN DIABETES

  • NEW INSULIN FORMULATIONS AND COMBINATIONS
    • NOVEL INSULIN DELIVERY TECHNOLOGY
      • Oral-Lyn
      • Oramed
      • Inhaled Insulin
  • IMPROVED ORAL ANTIDIABETIC DRUGS
    • NEW PRODUCTS NOW IN R&D OR RECENTLY APPROVED
      • Lixisenatide
      • Empagliflozin
      • Albiglutide
      • Dulaglutide
  • NEW DEVELOPMENTS IN GLUCOSE TESTING
    • CONTINUOUS GLUCOSE MONITORING (CGM)
      • Reimbursement
    • NON-INVASIVE MONITORING
      • ARTIFICIAL PANCREAS
      • Roche
      • Novo Nordisk/LifeScan
      • TABLE 11 DEVELOPMENT OF ARTIFICIAL PANCREAS: CURRENT STATUS
  • RADICAL APPROACHES
    • ALTERNATIVES TO INSULIN
      • Rituximab
    • IMMUNOTHERAPY
    • TRANSPLANTATION
    • CELL AND STEM CELL THERAPIES
    • GENE THERAPY
      • Gene Therapy Approaches for Expressing Insulin
      • Gene Therapy Approaches for Immunomodulation
      • Gene Therapy Approaches for Cell-Based Therapies

CHAPTER 6 THE GLOBAL DIABETES MARKET

  • MARKET COMPONENTS
    • MARKET SIZE
    • TABLE 12 GLOBAL DIABETES MARKET BY PRODUCT, 2016 ($ BILLIONS)
    • GROWTH
  • MARKET ANALYSIS BY PRODUCT CATEGORY
    • INSULINS AND INSULIN DELIVERY DEVICES
      • Major Suppliers
      • TABLE 13 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2013 ($ MILLIONS)
    • OTHER ANTIDIABETIC DRUGS
      • Major Suppliers
      • TABLE 14 SALES OF OTHER ANTIDIABETIC DRUGS, 2014 ($ MILLIONS)
    • INSULIN PUMPS
    • TABLE 15 GLOBAL INSULIN PUMP MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
    • MONITORING PRODUCTS
    • TABLE 16 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2015 ($ MILLIONS/%)
  • TRENDS
  • REGIONAL SEGMENTATION
  • TABLE 17 RISING PREVALENCE OF DIABETES BY REGION, 2015 AND 2021 (EST.) (MILLIONS OF CASES)
  • NATIONAL MARKETS
    • NORTH AMERICA
    • TABLE 18 DIABETES MARKET IN THE U.S. AND CANADA, THROUGH 2021 ($ BILLIONS)
    • SOUTH AND CENTRAL AMERICA
    • TABLE 19 DIABETES MARKET IN MEXICO AND BRAZIL, THROUGH 2021 ($ BILLIONS)
    • EUROPE
    • TABLE 20 DIABETES MARKET FOR MAJOR EUROPEAN ECONOMIES, THROUGH 2021 ($ BILLIONS)
    • ASIA
    • TABLE 21 DIABETES MARKET FOR MAJOR ASIAN COUNTRIES, THROUGH 2021 ($ BILLIONS)
  • NATIONAL MARKETS IN DETAIL
    • THE NORTH AND SOUTH AMERICAN MARKET
      • The U.S.
        • Vital Statistics
        • Health and Healthcare
        • The U.S. Pharmaceutical Market
        • TABLE 22 U.S. DIABETES MEDICATION MARKET, THROUGH 2021 ($ MILLIONS)
        • TABLE 23 U.S. DIABETES DEVICE MARKET, THROUGH 2021 ($ MILLIONS)
      • Canada
        • Vital Statistics
        • Health and Healthcare
        • The Pharmaceutical Market
        • Diabetes Market
        • TABLE 24 DIABETES MEDICATION MARKET IN CANADA, THROUGH 2021 ($ MILLIONS)
        • TABLE 25 DIABETES DEVICE MARKET IN CANADA, THROUGH 2021 ($ MILLIONS)
    • LATIN AMERICA
      • Brazil
        • Vital Statistics
        • Health and Healthcare
        • Pharmaceutical Market
        • TABLE 26 DIABETES MEDICATION MARKET IN BRAZIL, THROUGH 2021 ($ MILLIONS)
        • TABLE 27 DIABETES DEVICE MARKET IN BRAZIL, THROUGH 2021 ($ MILLIONS)
      • Mexico
        • Vital Statistics
        • Health and Healthcare
        • Pharmaceutical Market
        • Market Restraints
        • Diabetes Market
        • TABLE 28 DIABETES MEDICATION MARKET IN MEXICO, THROUGH 2021 ($ MILLIONS)
        • TABLE 29 DIABETES DEVICE MARKET IN MEXICO, THROUGH 2021 ($ BILLIONS)
    • ASIA
      • China
        • Vital Statistics
        • Health and Healthcare
        • Pharmaceutical Market
        • Domestic Industry
        • Importance of R&D
        • Challenges
        • Regulatory Changes
        • Diabetes Market
        • TABLE 30 DIABETES MEDICATION MARKET IN CHINA, THROUGH 2021 ($ BILLIONS)
        • TABLE 31 DIABETES DEVICE MARKET IN CHINA, THROUGH 2021 ($ BILLIONS)
      • India
        • Vital Statistics
        • Health and Healthcare
          • Growing Affluence - Changing Medical Needs
        • Regulatory Changes
        • Pharmaceutical Market
        • Demographic Factors
        • Pharmaceutical Industry
        • Patent Reform
        • Diabetes Market
        • TABLE 32 DIABETES MEDICATION MARKET IN INDIA, THROUGH 2021 ($ MILLIONS)
        • TABLE 33 DIABETES DEVICE MARKET IN INDIA, THROUGH 2021 ($ MILLIONS)
      • Japan
        • Vital Statistics
        • Health and Healthcare
        • Pharmaceutical Market
        • TABLE 34 TOP JAPANESE PHARMA COMPANIES, 2014 ($ MILLIONS/%)
        • Diabetes Market
        • TABLE 35 DIABETES MEDICATION MARKET IN JAPAN, THROUGH 2021 ($ MILLIONS)
        • TABLE 36 DIABETES DEVICE MARKET IN JAPAN, THROUGH 2021 ($ MILLIONS)
    • THE EUROPEAN MARKET
      • France
        • Vital Statistics
        • Health and Healthcare
        • Healthcare Provision
        • Pharmaceutical Market
        • TABLE 37 DIABETES MEDICATION MARKET IN FRANCE, THROUGH 2021 ($ MILLIONS)
        • TABLE 38 DIABETES DEVICE MARKET IN FRANCE, THROUGH 2021 ($ MILLIONS)
      • Germany
        • Vital Statistics
        • Health and Healthcare
          • Provision of Healthcare
        • Pharmaceutical Market
          • Price Controls
        • Diabetes Market
        • TABLE 39 DIABETES MEDICATION MARKET IN GERMANY, THROUGH 2021 ($ MILLIONS)
        • TABLE 40 DIABETES DEVICE MARKET IN GERMANY, THROUGH 2021 ($ MILLIONS)
      • Italy
        • Vital Statistics
        • Health and Healthcare
        • Healthcare System
          • Healthcare Provision
        • Pharmaceutical Market
        • Implications for Research
        • Diabetes Market
        • TABLE 41 DIABETES MEDICATION MARKET IN ITALY, THROUGH 2021 ($ MILLIONS)
        • TABLE 42 DIABETES DEVICE MARKET IN ITALY, THROUGH 2021 ($ MILLIONS)
      • Russia
        • Vital Statistics
        • Health and Healthcare
          • Healthcare Delivery
        • Pharmaceutical Market
        • Pharma 2020
        • Diabetes Market
        • TABLE 43 DIABETES MEDICATION MARKET IN RUSSIA, THROUGH 2021 ($ BILLIONS)
        • TABLE 44 DIABETES DEVICE MARKET IN RUSSIA, THROUGH 2021 ($ MILLIONS)
      • Spain
        • Vital Statistics
        • Health and Healthcare
          • Healthcare Provision
        • Pharmaceutical Services
        • Pharmaceutical Market
        • Diabetes Market
        • TABLE 45 DIABETES MEDICATION MARKET IN SPAIN, THROUGH 2021 ($ MILLIONS)
        • TABLE 46 DIABETES DEVICE MARKET IN SPAIN, THROUGH 2021 ($ MILLIONS)
      • United Kingdom
        • Vital Statistics
        • Health and Healthcare
          • Healthcare Provision
          • Private Sector Involvement
        • Pharmaceuticals
        • Pharmaceutical Market
        • Diabetes Market
        • TABLE 47 DIABETES MEDICATION MARKET IN THE U.K., THROUGH 2021 ($ MILLIONS)
        • TABLE 48 DIABETES DEVICE MARKET IN THE U.K., THROUGH 2021 ($ MILLIONS)

CHAPTER 7 COMPANY PROFILES

  • LEADING COMPANIES
    • A. MENARINI DIAGNOSTICS S.R.L.
    • ABBOTT LABORATORIES
      • Abbott Diabetes Care Inc.
    • ASCENSIA
    • BECTON DICKINSON
    • ELI LILLY AND CO.
      • Diabetes Products
    • GLAXO SMITHKLINE
      • Diabetes Products
    • JOHNSON & JOHNSON
      • Diabetes Products
    • MEDTRONIC
      • Diabetes Products
    • Pipeline
    • MERCK KGAA
      • Diabetes Product
    • MERCK & CO.
    • NOVARTIS PHARMA AG
      • Diabetes Products
    • NOVO NORDISK A/S
      • Diabetes Products
      • Pharmaceuticals
      • Pipeline
    • ROCHE
      • Diabetes Products
      • Blood Glucose Monitoring Systems
      • Diabetes Data Management
      • Insulin Pump Systems
      • Lancet Devices
      • Other
    • SANOFI
      • Diabetes Products
    • TAKEDA PHARMACEUTICAL CO. LTD.
    • OTHER COMPANIES
    • 77 ELEKTRONIKA KFT.
    • AGAMATRIX INC.
    • ANIMAS CORP.
    • DEBIOTECH S.A.
    • INLIGHT SOLUTIONS INC.
    • LIFESCAN INC.
    • NIPRO CORP.
    • OWEN MUMFORD LTD.
    • PALCO LABS INC.
    • TERUMO CORP.

CHAPTER 8 APPENDIX I ABOUT DIABETES

  • BLOOD SUGAR REGULATION
  • INSULIN
  • TYPE 1 DIABETES
  • TYPE 2 DIABETES
  • GESTATIONAL DIABETES
  • OBESITY-RELATED TYPE 2 DIABETES IN CHILDREN
  • MATURE-ONSET DIABETES OF THE YOUNG (MODY)
  • OTHER DIABETIC STATES
    • LADA
    • PRE-DIABETES
    • DIAGNOSIS
    • GLUCOSE TESTS
    • OFFICIAL CRITERIA
    • DIFFERENTIAL DIAGNOSIS
      • Type 1 Diabetes
      • Type 2 Diabetes
    • CURRENT TREATMENT
      • Type 1 Diabetes
      • Type 2 Diabetes
        • Sulphonylureas
        • Biguanides
        • Alpha-glucosidase Inhibitors
        • Glitazones (Thiazolidinediones)
        • Prandial Glucose Regulators
        • Incretin Mimetics
        • DPP-4 Inhibitors
        • DIET
    • MONITORING DIABETES
      • Blood Sugar Control
    • THE DIABETES CONTROL AND COMPLICATIONS TRIAL
    • GLYCATED HEMOGLOBIN (HBA1C)
    • FRUCTOSAMINE
    • PREVALENCE OF DIABETES
    • TYPE 1
    • TYPE 2
    • DIABETIC COMPLICATIONS
    • RETINOPATHY
    • NEUROPATHY
    • NEPHROPATHY
    • INCREASED MORTALITY RISK
    • METABOLIC SYNDROME

CHAPTER 9 APPENDIX II GLOSSARY

  • TABLE 49 GLOSSARY OF TERMS

LIST OF TABLES

  • SUMMARY TABLE GLOBAL DIABETES MARKET BY PRODUCT GROUP, THROUGH 2021 ($ BILLIONS)
  • TABLE 1 GLOBAL AND REGIONAL DIABETES PREVALENCE CASES, 2015-2040 (MILLIONS)
  • TABLE 2 GLOBAL DIABETES MARKET, 2015 ($ BILLIONS)
  • TABLE 3 ADULT DIABETES MARKET BY REGION, 2015 ($ MILLIONS/%)
  • TABLE 4 MAJOR BRANDS OF INSULIN
  • TABLE 5 INSULIN PENS
  • TABLE 6 INSULIN INJECTORS
  • TABLE 7 SULFONYLUREAS
  • TABLE 8 ORAL HYPOGLYCEMICS
  • TABLE 9 GLOBAL SUPPLIERS OF BLOOD LANCETS
  • TABLE 10 MAJOR BLOOD GLUCOSE MONITOR SUPPLIERS AND BRANDS
  • TABLE 11 DEVELOPMENT OF ARTIFICIAL PANCREAS: CURRENT STATUS 53
  • TABLE 12 GLOBAL DIABETES MARKET BY PRODUCT, 2016 ($ BILLIONS)
  • TABLE 13 GLOBAL SALES OF LEADING INSULIN PRODUCTS, 2013 ($ MILLIONS)
  • TABLE 14 SALES OF OTHER ANTIDIABETIC DRUGS, 2014 ($ MILLIONS)
  • TABLE 15 GLOBAL INSULIN PUMP MARKET BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 16 LEADING SUPPLIERS OF GLUCOSE MONITORING PRODUCTS, 2015 ($ MILLIONS/%)
  • TABLE 17 RISING PREVALENCE OF DIABETES BY REGION, 2015 AND 2021 (EST.) (MILLIONS OF CASES)
  • TABLE 18 DIABETES MARKET IN THE U.S. AND CANADA, THROUGH 2021 ($ BILLIONS)
  • TABLE 19 DIABETES MARKET IN MEXICO AND BRAZIL, THROUGH 2021 ($ BILLIONS)
  • TABLE 20 DIABETES MARKET FOR MAJOR EUROPEAN ECONOMIES, THROUGH 2021 ($ BILLIONS)
  • TABLE 21 DIABETES MARKET FOR MAJOR ASIAN COUNTRIES, THROUGH 2021 ($ BILLIONS)
  • TABLE 22 U.S. DIABETES MEDICATION MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 23 U.S. DIABETES DEVICE MARKET, THROUGH 2021 ($ MILLIONS)
  • TABLE 24 DIABETES MEDICATION MARKET IN CANADA, THROUGH 2021 ($ MILLIONS)
  • TABLE 25 DIABETES DEVICE MARKET IN CANADA, THROUGH 2021 ($ MILLIONS)
  • TABLE 26 DIABETES MEDICATION MARKET IN BRAZIL, THROUGH 2021 ($ MILLIONS)
  • TABLE 27 DIABETES DEVICE MARKET IN BRAZIL, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 DIABETES MEDICATION MARKET IN MEXICO, THROUGH 2021 ($ MILLIONS)
  • TABLE 29 DIABETES DEVICE MARKET IN MEXICO, THROUGH 2021 ($ BILLIONS)
  • TABLE 30 DIABETES MEDICATION MARKET IN CHINA, THROUGH 2021 ($ BILLIONS)
  • TABLE 31 DIABETES DEVICE MARKET IN CHINA, THROUGH 2021 ($ BILLIONS)
  • TABLE 32 DIABETES MEDICATION MARKET IN INDIA, THROUGH 2021 ($ MILLIONS)
  • TABLE 33 DIABETES DEVICE MARKET IN INDIA, THROUGH 2021 ($ MILLIONS)
  • TABLE 34 TOP JAPANESE PHARMA COMPANIES, 2014 ($ MILLIONS/%)
  • TABLE 35 DIABETES MEDICATION MARKET IN JAPAN, THROUGH 2021 ($ MILLIONS)
  • TABLE 36 DIABETES DEVICE MARKET IN JAPAN, THROUGH 2021 ($ MILLIONS)
  • TABLE 37 DIABETES MEDICATION MARKET IN FRANCE, THROUGH 2021 ($ MILLIONS)
  • TABLE 38 DIABETES DEVICE MARKET IN FRANCE, THROUGH 2021 ($ MILLIONS)
  • TABLE 39 DIABETES MEDICATION MARKET IN GERMANY, THROUGH 2021 ($ MILLIONS)
  • TABLE 40 DIABETES DEVICE MARKET IN GERMANY, THROUGH 2021 ($ MILLIONS)
  • TABLE 41 DIABETES MEDICATION MARKET IN ITALY, THROUGH 2021 ($ MILLIONS)
  • TABLE 42 DIABETES DEVICE MARKET IN ITALY, THROUGH 2021 ($ MILLIONS)
  • TABLE 43 DIABETES MEDICATION MARKET IN RUSSIA, THROUGH 2021 ($ BILLIONS)
  • TABLE 44 DIABETES DEVICE MARKET IN RUSSIA, THROUGH 2021 ($ MILLIONS)
  • TABLE 45 DIABETES MEDICATION MARKET IN SPAIN, THROUGH 2021 ($ MILLIONS)
  • TABLE 46 DIABETES DEVICE MARKET IN SPAIN, THROUGH 2021 ($ MILLIONS)
  • TABLE 47 DIABETES MEDICATION MARKET IN THE U.K., THROUGH 2021 ($ MILLIONS)
  • TABLE 48 DIABETES DEVICE MARKET IN THE U.K., THROUGH 2021 ($ MILLIONS)
  • TABLE 49 GLOSSARY OF TERMS

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL DIABETES MARKET BY PRODUCT GROUP, 2015-2021 ($ BILLIONS)
Back to Top